Zevra Therapeutics, Inc.
ZVRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | -0.08 | 0.09 | 0.88 |
| FCF Yield | -18.06% | -14.57% | -11.88% | 3.99% |
| EV / EBITDA | -5.40 | -5.35 | -4.19 | -18.83 |
| Quality | ||||
| ROIC | -70.49% | -36.25% | -40.69% | 5.99% |
| Gross Margin | 68.59% | 89.28% | 97.82% | 92.81% |
| Cash Conversion Ratio | 0.66 | 0.73 | 0.45 | -1.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 32.45% | -1.40% | -8.56% | 30.68% |
| Free Cash Flow Growth | -105.92% | -79.86% | -281.97% | 624.19% |
| Safety | ||||
| Net Debt / EBITDA | -0.35 | -0.02 | 2.01 | 14.04 |
| Interest Coverage | -11.84 | -33.05 | -127.06 | 20.56 |
| Efficiency | ||||
| Inventory Turnover | 3.76 | 0.12 | 0.00 | 0.00 |
| Cash Conversion Cycle | -384.04 | 1,482.13 | -5,638.89 | -72.00 |